A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies.

Front Oncol · 2026 · PMC13057523 · PMID 41959912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

3.7 months) and showed a trend toward overall survival benefit (12.9 vs. 8.9 months), with an objective response rate of 30.8% and a manageable safety profile ( 10 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.